Anales de la RANM

26 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 LA DETECCIÓN DE LA ENFERMEDAD MÍNIMA RESIDUAL Díaz-Rubio E An RANM. 2026;143(01): 16 - 27 6. Taieb J, Souglakos J, Boukovinas I, et al. Com- bined analyses of circulating tumor DNA and Immunoscore in patients with stage III colon cancer: a post hoc analysis of the PRODIGE- GERCOR IDEA-France/HORG-IDEA-Greece trials. J Clin Oncol. 2025;43(13):1564–1577. 7. Krell M, Llera B, Brown Z. Circulating tumor DNA and management of colorectal cancer. Cancer. 2024;130:1–13. 8. Aredo JV, Jamali A, Zhu J, et al. Liquid biopsy approa- ches for cancer characterization and residual disease detection. ASCO Educ Book. 2025;45:e1–e23. 9. Pathak P, Chan G, Deming DA, Chee CE. State- of-the-art management of colorectal cancer. ASCO Educ Book. 2024;44:3–15. 10. Conca V, Ciraci O, Bocaccio C, et al. Waiting for the liquid revolution in adjuvant colon cancer. Cancer Treat Rev. 2024;126:102735. 11. Malla M, Loree JM, Kasi PM, Parikh AR. Using circulating tumor DNA in colorectal cancer. J Clin Oncol. 2022;40:2846–2857. 12. Shergill A, Parikh AR. Investigating ctDNA in early-stage colon cancer. Oncology (Williston Park). 2022;36(10):620–626. 13. Arisi M, Dotan E, Fernandez S. Circulating tu- mor DNA in precision oncology. Int J Mol Sci. 2022;23:444. 14. Dasari A, Morris VK, Allegra CJ, et al. ctD- NA applications in colorectal cancer: NCI task force white paper. Nat Rev Clin Oncol. 2020;17:757–770. 15. Naidoo M, Gibbs P, Tie J. ctDNA and adjuvant therapy for colorectal cancer. Cancers (Basel). 2021;13:346. 16. Schraa SJ, van Rooijen KL, Koopman M, et al. Cell-free circulating tumor DNA before sur- gery as a prognostic factor. Cancers (Basel). 2022;14:2218. 17. Pascual J, Attard G, Bidard FC, et al. ESMO recommendations on the use of circulating tu- mour DNA assays for patients with cancer: a re- port from the ESMO Precision Medicine Wor- king Group. Ann Oncol. 2022;33(8):750–768. 18. Alese OB, Cook N, et al. Circulating tumor DNA: an emerging tool in gastrointestinal can- cers. ASCO Educ Book. 2022;42:279–298. 19. Abidoye O, Ahn DH, Borad MJ, et al. Circula- ting tumor DNA testing for minimal residual disease and its application in colorectal cancer. Cells. 2025;14(3):161. 20. Crisafulli G. Liquid biopsy and challenge of assay heterogeneity for minimal residual di- sease assessment in colon cancer treatment. Genes (Basel). 2025;16(1):71. 21. Yang J, Yu C, Li H, et al. Evaluation of mole- cular residual disease by a fixed gene panel in resectable colorectal cancer. Cancer Res Treat. 2024;56:1183–1196. 22. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92. 23. Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon can- cer. JAMA Oncol. 2019;5(12):1710–1717. 24. Tie J, Cohen JD, Wang Y, et al. Serial circula- ting tumour DNA analysis during multimoda- lity treatment of locally advanced rectal can- cer. Gut. 2019; 68:663–671. 25. Tie J, Cohen JD, Lo SN, et al. Prognostic signi- ficance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: an indi- vidual patient pooled analysis. Int J Cancer. 2021;148(4):1014–1026. 26. Reinert T, Henriksen TV, Christensen E, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I–III colorec- tal cancer. JAMA Oncol. 2019;5(8):1124–1131. 27. Henriksen TV, Tarazona N, Frydendahl A, et al. Circulating tumor DNA in stage III colorec- tal cancer beyond minimal residual disease de- tection. Clin Cancer Res. 2022;28(3):507–517. 28. Tie J, Cohen JD, Lahouel K, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022; 386:2261–2272. 29. Tie J, Wang Y, Lo SN, et al. Circulating tumor DNA analysis guiding adjuvant therapy in sta- ge II colon cancer: 5-year outcomes of the DY- NAMIC trial. Nat Med. 2025;31(5):1509–1518. 30. Tie J, Wang Y, Loree JM, et al. ctDNA-guided adjuvant chemotherapy escalation in sta- ge III colon cancer: primary analysis of the DYNAMIC-III trial. J Clin Oncol. 2025;43(16 Suppl):3503. 31. Kotani D, Oki E, Nakamura Y, et al. Molecular residual disease and efficacy of adjuvant che- motherapy in patients with colorectal cancer. Nat Med. 2023;29:127–134. 32. Yukami H, Nakamura Y, Mishima S, et al. Cir- culating tumor DNA dynamics in colorectal cancer with molecular residual disease: upda- ted analysis of the GALAXY study. J Clin On- col. 2024;42(Suppl 3):6. 33. Nakamura Y, Watanabe J, Akazawa N, et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat Med. 2024;30:3272–3283. 34. Kataoka K, Muro K, Nakamura Y, et al. Sur- vival benefit of adjuvant chemotherapy based on molecular residual disease detection in re- sected colorectal liver metastases. Ann Oncol. 2024;35:1015–1025. 35. VEGA Trial Investigators. ctDNA-guided ran- domized non-inferiority trial (VEGA) com- paring post-surgical observation vs standard chemotherapy in ctDNA-negative resected co- lorectal cancer (CIRCULATE-Japan). Presen- ted at: AACR/ASCO 2025. (Abstract). 36. VEGA Trial Investigators. A randomized, ctDNA-guided de-escalation study for post- surgical management of ctDNA-negative re- sected colorectal cancer (CIRCULATE-Japan platform). Presented at: ESMO Gastrointesti- nal Cancers Congress 2025; 2–5 Jul 2025; Bar- celona, Spain. Abstract 20. 37. Bando H, Watanabe J, Kotaka M, et al. A rando- mized, double-blind, phase III study comparing trifluridine/tipiracil (FTD/TPI) versus placebo in patients with molecular residual disease following curative resection of colorectal cancer (ALTAIR). J Clin Oncol. 2025;43(suppl 4):LBA22.